GynecologyGynecology2079-56962079-5831Consilium Medicum28272Research ArticleManagement of patients with inflammatory diseases of the pelvic organsThe International Union against Sexually Transmitted Infections (IUSTI) overviewGombergMikhail Aleksandrovich-15122013156464909042020Copyright © 2013, Consilium Medicum2013[Bevan C.D, Johal B.J, Mumtaz G et al. Clinical, laparoscopic and microbiological findings in acute salpingitis: report on a United Kingdom cohort. Brit J Obstet Gynaecol 1995; 102 (5): 407–14.][Altunyurt S, Demir N, Posaci C. A randomized controlled trial of coil removal prior to treatment of pelvic inflammatory disease. Eur J Obstet Gynecol Reprod Biol 2003; 107: 81–4.][Bradshaw C.S, Jensen J.S, Tabrizi S.N et al. Azithromycin failure in Mycoplasma genitalium urethritis. Emerg Infect Dis 2006; 12 (7): 1149–52.][Foulds G, Johnson R.B. Selection of dose regimens of azithromycin. J Antimicrob Chem 1993; 31 (Suppl. E): 39–50.][Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG: An Int J Obstet Gynaecol 2010;117(12):1475–84.][Heystek M.J, Ross J.D.C. PID Study Group. A randomised double - blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009; 20: 690–5.][Lanjouw E, Ossewaarde J.M, Stary A et al. European guideline for the management of Chlamydia trachomatis infections. Int J STD AIDS 2010; 21 (11): 729–37.][CDC. Sexually Transmitted Diseases Treatment Guidelines 2002. MMWR – Morbidity & Mortality Weekly Report 2002; 55 (RR-6): 1–84.]